Enhanced expression of the Epstein-Barr Virus Nuclear Antigen, EBNA1, as a Target for T-cell-Based Immunotherapy for Prevention of Viral-Associated Diseases.

增强 Epstein-Barr 病毒核抗原 EBNA1 的表达，作为预防病毒相关疾病的 T 细胞免疫疗法的靶点。

• 批准号: nhmrc : 1005091
• 负责人: Dr Judy Tellam
• 金额: $ 23.77万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/enhanced-expression-epstein-associated-diseases/109088
• 关键词: Enhanced; expression; Epstein; Barr; Virus

Epstein-Barr virus, (EBV) is a human herpesvirus associated with a range of human cancers. EBNA1, an important EBV antigen, was thought to be “immunologically silent” however, recent studies from our laboratory show that EBNA1 is recognized by our body's defence system and these observations raise the possibility that EBNA1 may be an exploitable, immuno-therapy target for treating EBV-associated cancers.

EB病毒（EBV）是一种与一系列人类癌症相关的人类疱疹病毒。EBNA1是一种重要的EBV抗原，被认为是“免疫沉默”的，然而，我们实验室最近的研究表明，EBNA1被我们身体的防御系统识别，这些观察结果提高了EBNA1可能是治疗EBV相关癌症的可利用的免疫治疗靶点的可能性。